魚躍醫療(002223.SZ):2015年度員工持股計劃出售完畢
格隆匯 12 月 22日丨魚躍醫療(002223.SZ)公佈,截至公告日,公司2015年度員工持股計劃所持有的公司股票已全部出售完畢。員工持股計劃於2019年6月28日至2020年12月22日通過集中競價交易(包括以持有的股份認購ETF份額)累計減持1174.9347萬股,佔公司總股本比例1.17%。此次員工持股計劃在實施期間嚴格遵守市場交易規則以及中國證監會、深交所關於信息敏感期不得買賣股票的規定,未利用內幕信息進行交易。根據公司2015年度員工持股計劃的有關規定,此次員工持股計劃已實施完畢並終止,後續將進行相關資產清算及分配工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.